Simulation output for your selection:
Mechanism: Denosumab is injected every 6 months. After every denosumab injection, the osteoclasts die because of the absence of RANKL. In the time between one injection and the next, osteoclasts are formed from precursors. As a result of accumulation of osteoclast precursors due to blocking of differentiation by denosumab, the osteoclast recovery increases over time.
Note that the exercise level is right but for this osteoporotic patient with high resorption and high formation giving PTH that will increase resorption and formation even further would be a controversial therapeutic decision.
This is not the best combination of treatment and exercise level for this osteoporotic patient. Try again!